Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism).Bull Johns Hopkins Hosp. 1932; 50: 137-195
- The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis.Mayo Clin Proc. 1949; 24: 181-197
- Vertebral fractures resulting from prolonged cortisone and corticotropin therapy.JAMA. 1954; 156: 467-469
- Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.Am J Med. 1994; 96: 115-123
- Utilization of oral corticosteroids in the United Kingdom.Q J Med. 2000; 93: 105-111
- Bone histomorphometry in glucocorticoid-induced osteoporosis.J Bone Miner Res. 1989; 4: 137-141
- Histomorphometric analysis of glucocorticoid-induced osteoporosis.Micron. 2005; 36: 645-652
- Estrogen deficiency and bone loss: an inflammatory tale.J Clin Invest. 2006; 116: 1186-1194
- Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.Endocrinology. 1999; 140: 4382-4389
- Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects.Neuroimmunomodulation. 2005; 12: 1-19
- High-dose glucocorticoids increase serum levels of soluble Il-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption.Eur J Endocrinol. 2006; 154: 745-751
- Dexamethasone enhances osteoclasts formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts.J Biol Chem. 2003; 278: 44667-44674
- Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.Endocrinology. 2006; 147: 5592-5599
- Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone.J Clin Invest. 1998; 102 (25): 274-282
- Glucocorticoid-induced osteoporosis: pathophysiology.in: Maricic M. Gluck O. Bone disease in rheumatology. Lippincott, New York2005: 105-110
- Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression.Bone. 2002; 30: 685-691
- Glucocorticoid suppresses the canonical Wnt signal in human osteoblast.Biochem Biophys Res Commun. 2005; 329: 177-181
- Gene expression profiling of glucocorticoid-inhibited osteoblasts.J Mol Endocrinol. 2004; 33: 175-193
- Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms.J Biol Chem. 1995; 270: 26607-26612
- Glucocorticoid suppression of IGF I transcription in osteoblasts.Mol Endocrinol. 2001; 15: 1781-1789
- Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid-treated mice independently of BMD: an unappreciated determinant of bone strength.J Bone Miner Res. 2002; 17: S156
- Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis.Ann Intern Med. 1993; 119: 963-968
- Oral glucocorticoid use is associated with an increased risk of fracture.Osteoporos Int. 2004; 15: 323-328
- A meta-analysis of prior corticosteroid use and fracture risk.J Bone Miner Res. 2004; 19: 893-899
- Use of oral corticosteroids and risk of fractures.J Bone Miner Res. 2000; 15: 993-1000
- Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.Rheumatology. 2000; 39: 1383-1389
- Inhaled corticosteroids and hip fracture: a population-based case-control study.Am J Respir Crit Care Med. 2002; 166: 1563-1566
- Use of inhaled corticosteroids and risk of fractures.J Bone Miner Res. 2001; 3: 581-588
- High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy; a cross-sectional outpatient study.Bone. 2006; 39: 253-259
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.(Technical report series 843) WHO, Geneva (Switzerland)1994
- Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.Arthritis Rheum. 2003; 48: 3224-3229
- Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.Arthritis Rheum. 1999; 42: 2309-2318
- Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial.J Bone Miner Res. 2000; 15: 1006-1013
- Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Care Res. 2010; 62: 1515-1526
- Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis.Ann Intern Med. 1996; 125: 961-968
- The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.Arthritis Rheum. 1999; 42: 1740-1751
- Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.Osteoporos Int. 2004; 15: 589-602
- Alendronate for the treatment and prevention glucocorticoid-induced osteoporosis.N Engl J Med. 1998; 339: 292-299
- Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids.Arthritis Rheum. 2001; 44: 202-211
- Effects of risedronate treatment on bone density an vertebral fracture in patients on corticosteroid therapy.Calcif Tissue Int. 2000; 67: 277-285
- Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis.N Engl J Med. 1997; 337: 382-387
- The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.J Bone Miner Res. 2002; 17: 1512-1526
- Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.J Bone Miner Res. 2001; 16: 104-112
- Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.Osteoporos Int. 2003; 14: 801-807
- Pharmacological profile of zoledronic acid: a highly potent inhibitor of bone resorption.Drug Dev Res. 2002; 55: 210-224
- Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy randomised controlled trial.Lancet. 2009; 373: 1253-1263
- Mechanisms of anabolic therapies for osteoporosis.N Engl J Med. 2007; 357: 905-916
- Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.J Clin Invest. 1998; 102: 1627-1633
- Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid induced osteoporosis: results of a randomized controlled clinical trial.J Bone Miner Res. 2000; 15: 944-951
- Teriparatide or alendronate in glucocorticoid-induced osteoporosis.N Engl J Med. 2007; 357: 2028-2039
- Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: analysis by gender and menopausal status.Osteoporos Int. 2009; 20: 2095-2103
- Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty six-month results of a randomized, double-blind controlled trial.Arthritis Rheum. 2009; 60: 3346-3355
- A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.Calcif Tissue Int. 1996; 58: 73-80
- Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids.Arthritis Rheum. 1994; 37: 1499-1505
- Testosterone therapy in glucocorticoid-treated men.Arch Intern Med. 1996; 156: 1173-1177
- Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the women’s health initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Risks of testosterone-replacement therapy and recommendations for monitoring.N Engl J Med. 2004; 350: 482-492
- FRAX and the assessment of fracture probability in men and women from the UK.Osteoporos Int. 2008; 18: 1033-1046
- Guidance for adjustment of FRAX according to the dose of glucocorticoids.Osteoporos Int. 2011; 22: 809-816
- Longitudinal patterns in the prevention of osteoporosis in Glucocorticoid-treated patients.Arthritis Rheum. 2005; 52: 2485-2494
- Barriers in the management of glucocorticoid-induced osteoporosis.Arthritis Rheum. 2007; 57: 140-146
- Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.Arthritis Rheum. 2002; 46: 3136-3142
- Glucocorticoid-induced osteoporosis program (GIOP): a normal, comprehensive and successful program with improved outcomes at one year.Osteoporos Int. 2006; 17: 1428-1434
- Cost-effectiveness of multifaceted implementation programs for the prevention of glucocorticoid-induced osteoporosis.Osteoporos Int. 2010; 21: 1573-1584
Article info
Footnotes
Disclosure: The author has received research grant support and consultant fees from Merck, Proctor and Gamble, Eli Lilly, Novartis, and Amgen.
Identification
Copyright
© 2011 Published by Elsevier Inc.
